The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s showing significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a more substantial reduction in body weight and benefit metabolic markers,